ONP’s Revised MaPP Routes Steps For Investigational New Drug Applications
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Nonprescription Products outlines oversight and workflow procedures for filing investigational new drug applications in a newly issued Manual of Policies and Procedures released by the Center for Drug Evaluation and Research
You may also be interested in...
ONP Has Actual-Use Trial Panel, Rx-To-OTC Switch MaPP In Mind – Ganley
FDA's Office of Nonprescription Products may examine issues surrounding actual-use trials for OTC drugs at an advisory committee meeting later this year
FTC Views Testimonials As Efficacy Claims, Senior Attorney Warns
The Federal Trade Commission's senior staff attorney for advertising practices recommends firms stay away from using consumer testimonials to assert the benefits of their products
FTC Views Testimonials As Efficacy Claims, Senior Attorney Warns
The Federal Trade Commission's senior staff attorney for advertising practices recommends firms stay away from using consumer testimonials to assert the benefits of their products